We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Symphogen Receives Milestone Payment in Merck KGaA Sym004 Collaboration
News

Symphogen Receives Milestone Payment in Merck KGaA Sym004 Collaboration

Symphogen Receives Milestone Payment in Merck KGaA Sym004 Collaboration
News

Symphogen Receives Milestone Payment in Merck KGaA Sym004 Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Symphogen Receives Milestone Payment in Merck KGaA Sym004 Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Symphogen has announced that it has received a milestone payment from Merck KGaA, Darmstadt, Germany, related to the successful achievement of specific development objectives for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).

Out-licensed world-wide by Symphogen to Merck in September 2012, Sym004 was the subject of two data presentations at the 2013 ASCO Annual Meeting in Chicago, IL, earlier this month.

Specifically, Sym004 reported Phase 2 proof-of-concept data in squamous cell carcinoma of the head & neck (SCCHN) and in metastatic colorectal cancer that signaled clinical activity and were supportive of the anticipated mixture’s mechanism of action.

“We are pleased to achieve meaningful progress so early in our collaboration,” said Kirsten Drejer, Chief Executive Officer of Symphogen.

Drejer continued, “This payment substantially enhances the financial position of Symphogen and demonstrates our commitment to assisting Merck KGaA to advance this promising program.”

Advertisement